Cellectar Biosciences, Inc. Goodwill & Intangibles Disclosure
4. GOODWILL
Goodwill represents the excess of the purchase price of an acquired business over the fair value of the underlying net tangible and intangible assets.
As of December 31, 2018, the Company’s carrying value of its net assets exceeded its market capitalization. The Company adopted ASU No, 2017‑04 during the year ended December 31, 2018, therefore, no additional calculation was necessary.
As a result of this test the Company’s total goodwill was determined to be impaired and an impairment charge of $1,675,462 was recorded for the year ended December 31, 2018. The Company had no remaining goodwill as of December 31, 2019 or 2018.
Historical Timeline
| Fiscal Year | Filed | |
|---|---|---|
| 2019 | Mar 9, 2020 | Showing above |
| 2018 | Feb 26, 2019 | |
| 2017 | Mar 21, 2018 | |
| 2016 | Mar 15, 2017 | |
| 2015 | Mar 11, 2016 | |
About Goodwill & Intangibles Disclosures
Goodwill and intangible asset disclosures reveal the premium paid in acquisitions and how management assesses whether that premium retains its value. Since goodwill is no longer amortized under US GAAP, the annual impairment test is the only mechanism that adjusts carrying values downward — making the assumptions behind that test critically important for investors.
Key signals: a history of goodwill impairments suggests management consistently overpays for acquisitions. Watch the gap between reporting unit fair value and carrying amount — when fair value exceeds carrying amount by less than 10-20%, a small decline in business performance could trigger a write-down. For finite-lived intangibles, examine useful life assumptions across customer relationships, technology, and trade names; aggressive estimates inflate near-term earnings. Compare total intangibles-to-total-assets ratios against peers to assess acquisition dependency. Rising goodwill as a percentage of equity can signal balance sheet fragility.